×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Life UK
Aravive (ARAV) delivered earnings and revenue surprises of 60% and 27.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what...
10 hours ago
Araviv-ederci? Phase 3 cancer flop blows hole in plans of cast-strapped biotech
Fierce Biotech
Aravive's phase 3 ovarian cancer trial has bombed, taking another chunk out of its share price. And, with cash down to $18 million at the...
9 months ago
Aravive Shares Drop 53%, Company to Delist and Deregister Stock
MarketWatch
By Stephen Nakrosis Shares of Aravive were lower in after-hours trading following the company's announcement it would voluntarily delist its...
3 months ago
Why Is Aravive (ARAV) Stock Down 52% Today?
InvestorPlace
Aravive stock is falling hard on Thursday after the company announced plans to voluntarily delist shares of ARAV from the Nasdaq!
3 months ago
Aravive, Inc. to Delist from The Nasdaq Stock Market
GlobeNewswire
HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to...
3 months ago
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Life UK
Aravive (ARAV) delivered earnings and revenue surprises of 60% and 27.40%, respectively, for the quarter ended June 2023.
24 hours ago
Aravive to delist from Nasdaq and dissolve company
Investing.com
(NASDAQ:ARAV), a biopharmaceutical company, has announced its decision to voluntarily delist its common stock from the Nasdaq Global Select...
3 months ago
Aravive Third Quarter 2023 Earnings: Beats Expectations
Simply Wall Street
Aravive ( NASDAQ:ARAV ) Third Quarter 2023 Results Key Financial Results Revenue: US$2.76m (down 44% from 3Q 2022). Net...
5 months ago
Aravive's cancer therapy trial fails to meet primary endpoint
Clinical Trials Arena
Aravive has reported that its Phase III trial of batiraxcept for platinum-resistant ovarian cancer failed to meet its primary endpoint of...
9 months ago
Aravive, weeks from liquidation, lays off 70% of its staff as it seeks a savior
Fierce Biotech
The cash-strapped biotech has “several weeks” to find a partner or funding—and is laying off 70% of its staff to preserve what money it has...
8 months ago